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OBJECTIVE—Visceral obesity and elevated plasma free fatty
acids are predisposing factors for type 2 diabetes. Chronic
exposure to these lipids is detrimental for pancreatic -cells,
resulting in reduced insulin content, defective insulin secretion,
and apoptosis. We investigated the involvement in this phenom-
enon of microRNAs (miRNAs), a class of noncoding RNAs
regulating gene expression by sequence-specific inhibition of
mRNA translation.
RESEARCH DESIGN AND METHODS—We analyzed miRNA
expression in insulin-secreting cell lines or pancreatic islets
exposed to palmitate for 3 days and in islets from diabetic db/db
mice. We studied the signaling pathways triggering the changes
in miRNA expression and determined the impact of the miRNAs
affected by palmitate on insulin secretion and apoptosis.
RESULTS—Prolonged exposure of the -cell line MIN6B1 and
pancreatic islets to palmitate causes a time- and dose-dependent
increase of miR34a and miR146. Elevated levels of these miRNAs
are also observed in islets of diabetic db/db mice. miR34a rise is
linked to activation of p53 and results in sensitization to apopto-
sis and impaired nutrient-induced secretion. The latter effect is
associated with inhibition of the expression of vesicle-associated
membrane protein 2, a key player in -cell exocytosis. Higher
miR146 levels do not affect the capacity to release insulin but
contribute to increased apoptosis. Treatment with oligonucleo-
tides that block miR34a or miR146 activity partially protects
palmitate-treated cells from apoptosis but is insufficient to re-
store normal secretion.
CONCLUSIONS—Our findings suggest that at least part of the
detrimental effects of palmitate on -cells is caused by alter-
ations in the level of specific miRNAs. Diabetes 57:2728–2736,
2008
Type 2 diabetes is the most frequent metabolicdisorder and affects 150 million people world-wide. The disease results from a combination ofunfavorable genetic and environmental factors
that conspire to diminish sensitivity of insulin target
tissues and insulin secretion from pancreatic -cells. Un-
der normal conditions, a feedback loop exists between
insulin sensitivity and insulin secretion such that reduc-
tion in sensitivity of peripheral tissues is compensated by
an increase in hormone release. Progression to hypergly-
cemia and diabetes occurs if the secretory activity of
-cells becomes inadequate to counterbalance insulin re-
sistance (1,2). Visceral obesity and elevated plasma free
fatty acid (FFA) concentrations are predisposing factors
for the development of type 2 diabetes. Chronically ele-
vated FFAs promote insulin resistance in target tissues
and have detrimental effects on -cells, resulting in reduc-
tion in insulin content, abnormally elevated insulin release
in the absence of stimuli, diminished capacity to secrete
insulin in response to glucose, and increased -cell apo-
ptosis (2,3). The combination of these adverse effects on
-cells causes failure to maintain blood glucose homeosta-
sis and promotes the development of diabetes. The mech-
anisms underlying the negative impact of FFAs on insulin-
secreting cells are still incompletely understood, but
alterations in the expression of genes essential to accom-
plish specific -cell tasks are believed to occur. We
hypothesized that -cell failure due to chronic exposure to
FFAs could be linked to alterations in the level of micro-
RNAs (miRNAs), a recently discovered class of small
(22 nucleotides) noncoding RNAs that plays a key role in
the development and function of mammalian cells (4).
miRNAs act by pairing to sequences in the 3-untranslated
region (UTR) of target mRNAs and by inhibiting their
translation (5). According to recent estimates, up to one-
third of all human genes may be controlled by miRNAs.
Although we are only beginning to appreciate the immense
potential of miRNAs as controllers of gene networks, there
is already substantial evidence indicating that these small
noncoding RNA molecules play a central role in a variety
of physiological processes, including tissue differentiation,
cell proliferation, and apoptosis (4). Moreover, miRNAs
have already been implicated in human diseases (6).
Recent studies have highlighted a role for the miRNAs
miR375, miR9, and miR124a in pancreatic islet develop-
ment and in the execution of specialized -cell functions,
including insulin synthesis and insulin release in response
to secretagogues (7–11).
In this study, we investigated the potential involvement
of miRNAs in FFA-mediated -cell dysfunction. We found
that chronic exposure of -cells to palmitate results in
alterations in the expression of a specific set of miRNAs.
From the 1Department of Cell Biology and Morphology, Faculty of Biology and
Medicine, University of Lausanne, Lausanne, Switzerland; the 2Diabetes and
Obesity Research Program, Garvan Institute of Medical Research, St.
Vincent’s Hospital, Sydney, Australia; the 3Department of Physiology,
Faculty of Biology and Medicine, University of Lausanne, Lausanne, Swit-
zerland; and the 4Service of Internal Medicine, Centre Hospitalier Univer-
sitaire Vaudois, Lausanne, Switzerland.
Corresponding author: Dr. Romano Regazzi, romano.regazzi@unil.ch.
Received 3 September 2007 and accepted 28 June 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 15 July
2008. DOI: 10.2337/db07-1252.
P.L. and E.R. contributed equally to this work.
© 2008 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for profit,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
2728 DIABETES, VOL. 57, OCTOBER 2008
Detailed analysis of the role of two of these miRNAs
revealed that modification of their level has an important
impact on different -cell functions. Our data suggest that
at least part of the harmful effects of FFAs on insulin-
secreting cells may be mediated by alterations in the
miRNA expression pattern.
RESEARCH DESIGN AND METHODS
Cell culture and FFA treatment. The insulin-secreting cell line MIN6B1
(12) was cultured in 24- or 6-well dishes at a concentration of 1.3  105
cells/cm2 in Dulbecco’s modified Eagle’s medium (DMEM)–Glutamax medium
supplemented with 15% FCS, 50 IU/ml penicillin, 50 g/ml streptomycin, and
70 mol/l -mercaptoethanol. Rat pancreatic islets were isolated by hand-
picking after collagenase digestion of pancreas as described previously (13)
and maintained in RPMI 1640 supplemented with 10% FCS, 10 mmol/l HEPES,
pH 7.4, 1 mmol/l sodium pyruvate, 100 units/ml penicillin-streptomycin, 50
mol/l -mercaptoethanol, and 11 mmol/l glucose. Sodium palmitate, oleate,
and linoleate (Sigma, St. Louis, MO) were dissolved in 33% ethanol at 33
mmol/l and added to the medium at the indicated concentration. Control cells
were exposed to an equivalent concentration of ethanol. Pancreatic islets
from 14- to 20-week-old wild-type and C57BL/KsJ db/db mice were isolated as
previously described (14) and used immediately for RNA extraction.
RNA extraction, microarray, and quantitative RT-PCR assays. Extrac-
tion of RNA was performed with the mirVana miRNA isolation kit (Ambion,
Austin, TX) using the total RNA isolation option. For microarray profiling,
total RNAs were sent to the miRNA Microarray Service of LC Sciences
(Houston, TX). Conventional mRNA quantitative RT-PCR assays were carried
out as previously described (15) using the insulin two (NM_008387) primers:
SS, 5-TGG CTT CTT CTA CAC ACC CA-3, and AS, 5-TCT AGT TGC AGT
AGT TCT CCA-3; the p53 primers: SS, 5-GCA ACT ATG GCT TCC ACC TG-3,
and AS, AGC TTA TTG AGG GGA GGA GAG T; and, as control, the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers: SS, 5-TCC
ATG ACA ACT TTG GCA TTG-3, and AS, 5-CAG TCT TCT GGG TGG CAG
TGA-3. Mature miRNA measurements were performed using the mirVana
qRT-PCR miRNA Detection kit (Ambion) according to the manufacturer’s
instructions. U6 was chosen as control for small RNAs. All quantitative
RT-PCR assays were carried out on a Bio-Rad MyiQ Single-Color Real-Time
PCR Detection System (Bio-Rad Laboratories, Reinach, Switzerland).
miRNA overexpression and downregulation. To increase the level of
individual miRNAs, the cells were transfected with RNA duplexes containing
the mature sequence of the miRNA (Dharmacon or Eurogentec). The se-
quences were the following: miR34a sense, UGGCAGUGUCUUAGCUGGUUG
UU, and antisense, AACAACCAGCUAAGACACUGCCA; and miR146 sense,
UGAGAACUGAAUUCCAUGGGUU, and antisense, AACCCAUGGAAUUCAGU
UCUCA. Because assessing precisely the amount of miRNAs effectively
entering the cells is difficult when using this approach, in a limited set of
experiments, the level of miR34a and miR146 was increased by transfecting
the cells with plasmids encoding the corresponding miRNA precursors (16).
This technique led to an increase in the level of miR34a and miR146 of 10- to
30-fold and resulted in functional changes identical to those observed with
RNA duplexes. Endogenous activity of miRNAs was blocked using Clear-MiR
miRNA inhibitors (Eurogentec). Transient transfections were performed with
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) using a concentration of 1.33
ng/l plasmids and/or 60 pmol RNA duplexes. Cotransfection experiments
were performed with a mass ratio of 1:10 plasmid:RNA duplex.
Luciferase reporter assays. The luciferase reporter plasmid driven by the
miR34a promoter (promo miR34a) and the corresponding construct in which
the p53 binding site is mutated (promo miR34a mut) (17) were provided by Dr.
M. Oren (Weizmann Institute, Rehovot, Israel). The p53 sensor plasmid
bearing the Firefly luciferase cDNA under the control of p53-responsive
elements and the plasmid encoding wild-type p53 have been described
previously (18). To generate the 3UTR–vesicle-associated membrane protein
2 (VAMP2) luciferase construct, the whole 3UTR (1.4 kb) of the mouse
VAMP2 gene (NM_009497) was amplified by PCR from genomic DNA and
inserted in the psiCHECK-1 vector (Promega, Madison, WI) between the XhoI
and EcoRI sites. The sequences of the primers were sense, 5-CAC CCC TTC
TCG AGG TTC CCA TC-3, and antisense, 5-GCG CCA CAG AAT TCG GGG
CAT G-3. The BclII 3UTR construct was generated by inserting the nucleo-
tides 179–211 of the 3UTR of mouse BclII (BC095964) between the XhoI and
EcoRI sites of psiCHECK-1. Luciferase activities were measured with a
dual-luciferase reporter assay system (Promega). The Firefly luciferase activ-
ity was normalized for transfection efficiency with the SV40-driven Renilla
activity generated by the psiCHECK-1 vector (Promega). The Renilla activity
from the 3UTR-VAMP2 plasmid was normalized with the Firefly activity of
the SV40 PGL3 promoter plasmid (Promega).
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FIG. 1. Effect of palmitate on miR34a and miR146 expression. MIN6B1
cells (left) were cultured for 72 h in normal DMEM (25 mmol/l glucose
concentration; Control) or in DMEM supplemented with 1 mmol/l
palmitate (Pal). Freshly isolated rat pancreatic islets (right) were
cultured for 72 h in normal RPMI 1640 (11 mmol/l glucose concentra-
tion; Control), in RPMI 1640 containing 25 mmol/l glucose (Glc), in
RPMI 1640 containing 1 mmol/l palmitate (Pal), or in RPMI 1640
containing 25 mmol/l glucose and 1 mmol/l palmitate (Glc/Pal). The
expression of miR34a and miR146 was assessed by quantitative RT-
PCR. The level of U6 measured in parallel in the same samples was used
to normalize the data. The asterisks indicate the conditions signifi-
cantly different (P < 0.05) from control.
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FIG. 2. miR34a and miR146 expression is increased in pancreatic islets
of db/db mice. Pancreatic islets were isolated from four wild-type mice
and five diabetic db/db mice. Blood glucose level was 6.8  0.4 mmol/l
in control animals and 21.8  1.4 mmol/l in db/db mice (P < 0.001).
RNA extracts from each islet preparation were analyzed by quantita-
tive RT-PCR for the expression of the indicated miRNAs. Data are
expressed as percent U6 content measured in the same sample.
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Secretion assay. For the assessment of hormone secretory capacity, MIN6B1
cells (2.5 105) plated in 24-well dishes were transiently cotransfected with RNA
duplexes or antisense miR oligonucleotides and with a construct encoding the
human growth hormone (hGH). Three days later, the cells were washed and
preincubated for 30 min in Krebs buffer (127 mmol/l NaCl, 4.7 mmol/l KCl, 1
mmol/l CaCl2, 1.2 mmol/l KH2PO4, 1.2 mmol/l MgSO4, 5 mmol/l NaHCO3, 25
mmol/l HEPES, and 0.1% BSA) containing 2 mmol/l glucose. The medium was
then discarded, and the cells were incubated during 45 min either in the same
Krebs buffer (basal condition) or in a Krebs buffer containing 20 mmol/l glucose,
10 mol/l forskolin, and 100 mol/l isobutylmethylxanthine (IBMX) (stimulated
condition). After collecting the supernatant, the cells were lysed in PBS contain-
ing 0.5% Triton X-100 to evaluate the remaining hGH content. The amount of hGH
in the samples was assessed using an hGH ELISA kit (Roche Diagnostics,
Rotkreuz, Switzerland).
Western blots. For Western blot analysis, the cells were washed once in PBS,
and total extracts were obtained by lysing the cells by brief sonication. Thirty
micrograms protein was separated on acrylamide gels and transferred on
polyvinylidine fluoride membranes. The membranes were incubated overnight
at 4°C with the primary antibodies. Immunoreactive bands were visualized
using a chemiluminescent substrate (Amersham Biosciences) after incubation
with a secondary horseradish peroxidase antibody. The antibodies against
VAMP2, Rab3A, and Rab27A were purchased from Synaptic Systems (Goet-
tingen, Germany). The antibodies against Syntaxin-1A and SNAP25 were from
Sigma and BD Transduction Laboratories (Lexington, KY), respectively. The
antibody against Noc2 (19) was provided by Dr. M. Fukuda (Tohoku Univer-
sity, Sendai, Japan). The antibody against Granuphilin was described previ-
ously (20). Actin antibody was from Chemicon International (Temecula, CA).
Apoptosis assay. For the assessment of the apoptotic activity, MIN6B1 cells
(2.5  105) plated in 24-well dishes were transiently cotransfected with
oligonucleotides. The apoptotic activity of the cells was evaluated after 3 days
by scoring the cells displaying pycnotic nuclei (visualized with Hoechst 33342
dye).
Statistical analysis. The data were tested by ANOVA for statistical differ-
ences. The experiments including more than two groups were first analyzed by
ANOVA. Multiple comparisons of the means were then carried out using the
post hoc Bonferroni (Dunn) test with a P value discriminating limit of 0.05.
RESULTS
Prolonged exposure to FFAs has deleterious impacts on
pancreatic -cell function, including alterations in insulin
secretion and sensitization toward apoptosis (2,3). Three-
day exposure to palmitate resulted in analogous defects in
the well-differentiated mouse insulin-secreting cell line
MIN6B1 (12) (see below). miRNAs are newly discovered
gene regulators that have been shown to control insulin
miR146
0.2
0.4
0.6
0.8
1.0
1.2
%
 o
f U
6 
ex
pr
es
si
on
24 hrs 48 hrs 72 hrs
control
palm
*
*
miR34a
0.05
0.10
0.15
0.20
0.25
0.30
0.35
24 hrs 48 hrs 72 hrs
%
 o
f U
6 
ex
pr
es
si
on control
palm
*
0.2
0.4
0.6
0.8
1.0
1.2
Ctrl 0.25mM 0.5mM 1mM
%
 o
f U
6 
ex
pr
es
si
on
*
* *
miR34a
0.1
0.2
0.3
0.4
Ctrl 0.25mM 0.5mM 1mM
%
 o
f U
6 
ex
pr
es
si
on
*
*
*
miR146
A
B
0.10
0.20
Ctrl Palm Oleate Linoleate
miR34a
%
 o
f U
6 
ex
pr
es
si
on 0.25
0.15
0.05
*
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
miR146
Ctrl Palm Oleate Linoleate
%
 o
f U
6 
ex
pr
es
si
on *
C
FIG. 3. miR34a and miR146 expression is induced in a time- and dose-dependent manner by palmitate but not by unsaturated FFAs. A: MIN6B1
cells were cultured for the indicated time in normal medium (control) or in the presence of 1 mmol/l palmitate (palm). After RNA extraction,
miR34a and miR146 levels were determined by quantitative RT-PCR. Data are expressed as percent U6 content measured in the same samples.
*Conditions significantly different (P < 0.05, n  3) from control. B: The cells were incubated for 72 h in normal DMEM (control) or in DMEM containing
the indicated concentrations of palmitate. miR34a, miR146, and U6 levels were determined by quantitative RT-PCR. The results are expressed as percent U6
content in each sample. *Conditions significantly different (P< 0.05, n 3) from control. C: The cells were incubated for 72 h in normal medium (control)
or in the presence of 0.5 mmol/l palmitate (Palm), 0.5 mmol/l oleate, or 0.5 mmol/l linoleate. miR34a and miR146 levels were determined by quantitative
RT-PCR and normalized to the U6 content. *Conditions significantly different (P < 0.05, n  3) from control.
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secretion (7,9–11). These noncoding RNAs have also been
demonstrated to regulate apoptosis in different cell sys-
tems (21). We therefore investigated whether changes in
the level of miRNAs can contribute to the effects of FFAs.
For this purpose, we initially compared the global miRNA
expression profile of MIN6B1 cells cultured in the pres-
ence or absence of 1 mmol/l palmitate for 3 days. Microar-
ray analysis permitted the detection of 132 miRNAs
expressed in MIN6B1 cells (supplemental Table 1, which is
available in an online appendix at http://dx.doi.org 10.2337/
db07-1252). With prolonged incubation with palmitate, we
observed no significant changes in the level of most
miRNAs, including miR375, miR9, and miR124a, the three
miRNAs previously involved in the regulation of pancre-
atic -cell functions (7,9–11) (supplemental Table 1).
However, after chronic exposure to palmitate, the level of
a small group of miRNAs appeared to be altered. The
expression of this subset of miRNAs, including miR34a,
miR96, miR145, miR146, miR195, and miR210, was ana-
lyzed in more detail by quantitative RT-PCR in a large
series of samples obtained from MIN6B1 cells and freshly
isolated rat pancreatic islets. The relatively small varia-
tions in the levels of miR96, miR145, and miR195 detected
in the microarray profiling could not be replicated in all
samples (supplementary Fig. 1), whereas the decrease in
miR210 expression was confirmed in MIN6B1 cells but
could not be reproduced in rat pancreatic islets (supple-
mentary Fig. 2). In view of these findings, these miRNAs
were not further analyzed, and we focused on miR34a and
miR146, which are increased in MIN6B1 cells and in rat
pancreatic islets (Fig. 1). Exposure of pancreatic islets to
elevated glucose concentrations have been shown to ex-
acerbate the effect of FFAs (22). Incubations of rat pan-
creatic islets in the presence of 25 mmol/l glucose resulted
in a small increase of miR34a but did not potentiate the
effect of palmitate (Fig. 1). The presence of supraphysi-
ological concentrations of glucose did not modify the
expression of miR146. The relevance of our in vitro
observations was verified by measuring the expression of
these two miRNAs in pancreatic islets from a mouse
model of type 2 diabetes. Elevated plasma FFA concentra-
tions, -cell dysfunction, and diabetes have been displayed
in 14- to 20-week-old db/db obese mice (14). We found that
in pancreatic islets from diabetic db/db mice, the levels of
miR34a and miR146 were significantly higher compared
with age-matched wild-type mice (Fig. 2), whereas the
level of miR124a was unchanged (not shown).
In MIN6B1 cells, differences in miR34a and miR146
expression were already seen after 24–48 h of culture in
the presence of palmitate but were more pronounced
after 72 h, consistent with a potential involvement in
long-term effects of the fatty acid (Fig. 3A). Incubation
for 72 h with different doses of palmitate revealed that
the effect of the lipid was already maximal at concen-
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FIG. 4. Effect of miR34a and miR146 on hormone secretion. The mouse insulin-secreting cell line MIN6B1 was transiently transfected with a
plasmid encoding hGH and with control RNA duplexes (control, palmitate); with RNA duplexes with the mature sequence of miR15b, miR34a, or
minR146; or with antisense miR34a (anti-miR34a). The cells were cultured for 3 days in normal DMEM ( and u) or with DMEM containing 1
mmol/l palmitate (f). hGH secretion under basal conditions (top) and in the presence of stimulatory concentrations of glucose and cAMP-raising
agents (bottom) was measured by ELISA. The figure shows the results of three to five independent experiments performed in triplicate.
*Conditions significantly different from controls (P < 0.05).
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trations between 0.25 and 0.5 mmol/l (Fig. 3B). Treat-
ment of the cells with the unsaturated FFAs oleate and
linoleate did not significantly affect the expression of
miR34a and miR146 (Fig. 3C).
To evaluate the possible contribution of miR34a and
miR146 to palmitate-mediated -cell dysfunction, we ei-
ther mimicked the changes elicited by the fatty acid by
overexpressing the miRNAs or inhibited their function
with modified antisense oligonucleotides (23) that can
efficiently reduce the level of each miRNA (supplementary
Fig. 3).
We first assessed the impact of the three miRNAs on the
secretory properties of MIN6B1 cells. For this purpose, the
cells were transfected with a plasmid leading to constitu-
tive expression of the hGH. When introduced in -cells,
hGH is packaged in dense-core granules and is coreleased
with insulin, enabling us to monitor exocytosis from
transiently transfected insulin-secreting cells indepen-
dently from their capacity to produce insulin (24). As
shown in Fig. 4, 3-day exposure to 1 mmol/l palmitate led
to the release of an exaggerated amount of hormone under
basal conditions (2 mmol/l glucose) and to a reduced
capacity of the cells to respond to stimulatory concentra-
tions of 20 mmol/l glucose and cAMP-raising agents (10
mol/l forskolin and 100 mol/l IBMX). Overexpression of
miR146 or miR15b, a miRNA whose expression is not
affected by palmitate (supplemental Table 1), did not affect
the secretory properties of MIN6B1 cells (Fig. 4, left).
Blockade of miR146 function with an antisense oligonu-
cleotide was also without effect (not shown). Overexpres-
sion of miR34a resulted in a significant reduction in the
amount of hormone released under stimulatory conditions
without modification of the secretion rate at low glucose
(Fig. 4, left). Antisense miR34a treatment did not interfere
with hormone secretion under basal or stimulated condi-
tions (Fig. 4, right). Blockade of miR34a function was not
sufficient to rescue a normal secretory response in cells
treated with palmitate (Fig. 4, right).
FFAs are known to sensitize -cells to apoptosis (3).
Under our experimental conditions, incubation of MIN6B1
cells with palmitate increased the number of apoptotic
cells by about fourfold (Fig. 5A). A rise in miR34a or
miR146 expression significantly augmented the fraction of
cells undergoing apoptosis, suggesting that at least part of
the effect of palmitate may be mediated through changes
in the level of these miRNAs (Fig. 5A). Inhibition of
miR34a or miR146 activity was found to partially protect
palmitate-treated cells against apoptosis (Fig. 5B).
We then investigated in more detail the mechanisms
responsible for the induction and action of miR34a, the
miRNA with a broader impact on -cell functions. Very
recently, different independent studies have shown that
the expression of miR34a is controlled by the transcription
factor p53 (17,25–29). In agreement with these reports,
overexpression of p53 in MIN6B1 cells increased the
expression of a luciferase reporter construct driven by the
miR34a promoter but not the expression of an analogous
construct in which the p53 recognition site is mutated
(Fig. 6A). In agreement with these findings, overexpres-
sion of p53 led to an increase in miR34a levels (Fig. 6B).
We then investigated whether prolonged incubation in the
presence of palmitate can activate the p53 pathway. Quan-
titative RT-PCR measurements revealed that under our
experimental conditions, the mRNA level of p53 is in-
creased in MIN6B1 cells and in rat pancreatic islets (Fig.
6D). In addition, we found that in cells treated with
palmitate, the p53 transcriptional activity assessed using a
luciferase reporter construct (p53 sensor) is enhanced
(Fig. 6C), confirming the activation of the p53 pathway. As
expected, prolonged incubation in the presence of palmi-
tate augmented the activity of the miR34a (30) promoter
but not the activity of the construct lacking the p53
binding site (Fig. 6C).
Chronic exposure to palmitate leads to changes in the
expression of several proteins that play an essential role in
-cell exocytosis (30–32), including VAMP2, SNAP25,
Rab27A, Noc2, and Granuphilin (Fig. 7). Interestingly,
VAMP2 is among the putative targets of miR34a (33,34). In
agreement with the computational prediction, Western
blot analysis revealed that miR34a overexpression in
MIN6B1 cells results in a decrease in the level of VAMP2
(Fig. 7). In contrast, miR34 did not affect the expression of
all the other components of the machinery of exocytosis
tested (Fig. 7). To verify whether VAMP2 is a direct
miR34a target in insulin-secreting cells, we generated a
0
5
10
15
20
25
30
35
%
 o
f a
po
pt
ot
ic
 c
el
ls
 
*
*
*
A
B
0
5
10
15
20
25
- palmitate
+
%
 o
f a
po
pt
ot
ic
 c
el
ls
 
* *
palmitate
FIG. 5. Effect of miR34a and miR146 on apoptosis. A: MIN6B1 cells
were transfected with a control RNA duplex or RNA duplexes contain-
ing miR15b, miR34a, or miR146. The cells were cultured for 3 days in
normal DMEM ( and u) or with DMEM containing 1 mmol/l palmitate
(f). The number of cells displaying apoptotic nuclei was scored and
divided by the total number of cells analyzed. Data are means  SE of
three independent experiments. *Conditions significantly different
(P < 0.05, n  3) from control. B: MIN6B1 cells were transfected with
control oligonucleotides, anti-miR34a (anti-34a), or anti-miR146 (anti-
146). The cells were then cultured for 3 days in normal DMEM () or
in DMEM supplemented with 1 mmol/l palmitate (f). The number of
cells displaying apoptotic nuclei was scored and divided by the total
number of cells analyzed. Data are means  SE of four to five
independent experiments. *Conditions that are significantly different
(P < 0.05).
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luciferase reporter construct containing the 3UTR of
VAMP2. As shown in Fig. 8A, miR34a overexpression
diminished the luciferase activity produced from this
construct but not from a control luciferase construct with
a 3UTR that does not contain the sequences of VAMP2
mRNA. As expected, overexpression of miR146 that has no
impact on hormone secretion did not affect the activity of
the control luciferase reporter or of the vector containing
the 3UTR of VAMP2 (Fig. 8A). These findings confirm that
VAMP2 is a direct target of miR34a and suggest that
diminished expression of this SNARE may potentially
contribute to the secretory defects observed with in-
creased expression of this miRNA.
BclII is a key antiapoptotic factor that has been shown
to be a direct target of miR34a in other cell types (29). To
assess whether BclII is a direct miR34a target in insulin-
secreting cells as well, we investigated the effect of this
miRNA on the activity of a luciferase reporter construct
containing the 3UTR target sequence of BclII mRNA. As
shown in Fig. 8B, miR34a diminished the luciferase activ-
ity produced from the BclII 3UTR construct but not from
a control vector lacking the miR34a target motif. In
contrast, overexpression of miR146 was without effect.
DISCUSSION
Acute exposure of pancreatic -cells to FFAs sustains
insulin secretion in the fasted state and potentiates hor-
mone release in the presence of glucose. However, chronic
exposure to elevated concentrations of FFAs has detri-
mental impacts on -cell functions and is believed to favor
the development of type 2 diabetes (2). Although pro-
longed incubation with FFAs is known to lead to alter-
ations in the expression of several genes playing key roles
in the accomplishment of -cell functions (2), the precise
mechanisms causing the lipotoxic effects are still incom-
pletely understood. In this study, we investigated the
potential involvement of miRNAs, a recently discovered
family of regulators of gene expression, in FFA-mediated
-cell dysfunction. We found that the expression of most
miRNAs, including those previously shown to be involved
in the control of specialized -cell functions (7,9–11), is
not affected by palmitate. However, the level of two
miRNAs, miR34a and miR146, was increased with sus-
tained exposure of insulin-secreting cell lines or freshly
isolated rat pancreatic islets to the FFAs. In this study, we
did not investigate in detail the effect of glucose on the
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expression of miR34a and miR146. MIN6 cells are cultured
at 25 mmol/l and are not ideally suited to address this
issue. In rat pancreatic islets, the effects of glucose and
palmitate on miR34a expression were not additive, and
miR146 expression was not affected by glucose. Loss of
-cell function is known to be more severe when the cells
are exposed concomitantly to elevated concentrations of
glucose and palmitate (2,3). Our observations in rat islets
indicate that alone, changes in the level of these two
miRNAs cannot account for the synergistic impact of
glucose and palmitate on -cell dysfunction.
Interestingly, a strong increase in the levels of miR34a
and miR146 was detected in pancreatic islets from a
mouse model of type 2 diabetes as well, suggesting that the
effects observed in vitro may recapitulate events occurring
in vivo. Detailed analysis of the role of these miRNAs in
insulin-secreting cells revealed that their expression
level can directly affect the execution of specialized
-cell tasks, raising the possibility of a possible involve-
ment of these noncoding RNAs in the toxic effects
triggered by palmitate.
In MIN6B1 cells, 3-day incubation with concentrations
of palmitate ranging from 0.25 to 1 mmol/l raised the
cellular level of miR34a. We provide evidence indicating
that the increase in miR34a expression is linked to activa-
tion of the p53 pathway. p53 is a tumor suppressor and an
inducer of apoptosis that can be activated by several
stressful conditions (35). p53 can induce apoptosis
through different mechanisms, including repression of
transcription of antiapoptotic genes and induction of
proapoptotic genes. Interestingly, in addition to its well-
established role in preventing cancer development, p53
was recently discovered to have much broader cellular
functions, including the regulation of glucose metabolism
and oxidative stress (35,36). The role of p53 in -cells has
been poorly investigated. The p53 signaling pathway has
been shown to be activated by cytokines (37) and to
potentiate FFA-induced apoptosis in insulinoma cell lines
(38). Our data show that the p53 pathway is activated with
chronic exposure to FFAs and identify the rise of miR34a
as an additional mechanism through which p53 can trigger
apoptosis in -cells.
miR34a and miR146 have been predicted, using bioin-
formatic approaches, to target numerous mRNAs (http://
www.targetscan.org/; http://www.microrna.org/microrna/
home.do). In view of the complexity of the impact of
miRNAs on gene expression, a precise definition of the
mode of action of miR34a and miR146 in -cells was
beyond the scope of the present study. However, here, we
were able to highlight some possible mechanisms leading
to -cell dysfunction in cells expressing elevated levels of
miRNAs.
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FIG. 7. Comparison of the effects of palmitate and miR34 on the
expression of components controlling insulin exocytosis. Left: MIN6B1
cells were incubated for 72 h in the absence () or in the presence of
1 mmol/l palmitate (). Right: MIN6B1 cells were transfected with a
control RNA duplex or with an RNA oligonucleotide corresponding to
the mature form of miR34a. The expression of the indicated compo-
nents of the machinery controlling insulin exocytosis was assessed by
Western blotting. The figure shows representative blots. Similar re-
sults were obtained in at least three independent experiments.







Control miR34a miR146
VAMP2 3'UTR
A
*
Lu
ci
fe
ra
se
 a
ct
iv
ity
Vector

10
20
30
40
50
60
Control miR34a miR146
Lu
ci
fe
ra
se
 a
ct
iv
ity
Vector
Bcl2 3’UTR
*
B
FIG. 8. VAMP2 and BclII are direct targets of miR34a in insulin-
secreting cells. A: MIN6B1 cells were cotransfected with a constitu-
tively expressed Firefly luciferase construct; a Renilla luciferase
reporter plasmid containing (f) or lacking (Vector, ) the sequence of
the 3UTR of mouse VAMP2; and a control RNA duplex (control),
miR34a, or miR146. Luciferase activities were measured 3 days later.
Renilla luciferase activities were divided by the Firefly luciferase
activities to correct for differences in transfection efficiencies. *Con-
dition is significantly different (P < 0.05, n  3) from control. B:
MIN6B1 cells were cotransfected with a constitutively expressed
Firefly luciferase construct; a Renilla luciferase reporter plasmid
containing (f) or lacking (Vector, ) the putative miR34 recognition
sequence in the 3UTR of BclII; and a control RNA duplex (control),
miR34a, or miR146. Luciferase activities were measured 3 days later.
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miR34a is known to regulate directly or indirectly the
expression of a large set of genes and to favor apoptosis by
inhibiting the expression of the antiapoptotic protein BclII
(29). Our data suggest that a similar mechanism could
contribute to the apoptotic effect of this miRNA in insulin-
secreting cells because miR34a reduced the expression of
a reporter construct containing the 3UTR of BclII. Inter-
estingly, a decrease in BclII expression has been associ-
ated with FFA-induced apoptosis of human pancreatic
islet cells (39).
The molecular events responsible for the miR34a-medi-
ated defects in insulin exocytosis are likely to concern
highly specialized genes selectively expressed in -cells.
Here, we were able to elucidate at least one mechanism
through which miR34a can affect hormone secretion. In
fact, the predicted targets of miR34a include VAMP2, a
protein associated with secretory vesicles and that plays
an essential role in insulin exocytosis (40–42). By direct
experimental testing, we could demonstrate that miR34a
can modulate the expression of VAMP2 in insulin-secret-
ing cells, providing a potential explanation for the secre-
tory defects observed in cells expressing increased levels
of miR34a.
The precise mechanism through which miR146 can
affect -cell function and, in particular, -cell survival
remains to be elucidated. In other cell systems, miR146
has been shown to target interleukin-1 receptor–associ-
ated kinase 1 (IRAK1) and tumor necrosis factor receptor–
associated factor 6 (TRAF6) (43), two key components of
interleukin-1 and Toll-like receptor signaling that medi-
ate activation of nuclear factor-B (NF-B) and activation
protein-1 (AP-1) pathways (44). In pancreatic -cells,
activation of these pathways can lead to cell death (45,46);
although under certain experimental conditions, inhibition
of the NF-B pathway has been reported to increase the
susceptibility to cell death and accelerate the development
of diabetes (47). Whether miR146 operates via a similar
mechanism in -cells is not yet known. A set of experi-
ments performed in our laboratory did not reveal changes
in TRAF6 protein expression in MIN6B1 cells (R.R., E.
Rogglie, unpublished observations). Recently, several
other genes have been shown to be directly or directly
influenced by miR146 (48,49). Future experiments will
have to assess whether the effect of miR146 on -cell
survival is linked to changes in the expression of one of
these genes or is due to other, yet-to-be-identified, molec-
ular mechanisms.
Having demonstrated the impact of miR34a or miR146
on different -cell activities, we attempted to determine to
which extent the changes in the level of these two small
RNAs could contribute to fatty acid-mediated functional
impairments. For this purpose, palmitate-treated cells
were transfected with antisense oligonucleotides that spe-
cifically block the activity of each miRNA. Using this
approach, we were able to demonstrate that the rise of
miR34a and miR146 contributes to FFA-induced -cell
death. We found that reduction of miR34a and miR146
partially protects the cells against palmitate-induced apop-
tosis. In contrast, it was more difficult to determine the
precise contribution of miR34a to the deleterious effects of
palmitate on insulin secretion. We showed that the secre-
tory dysfunction observed in miR34a-overexpressing cells
is most probably mediated by a decrease in the expression
of the SNARE protein VAMP2. Reduction of VAMP2 ex-
pression occurs in cells chronically exposed to palmitate
as well. However, in this case, the effect is rather small,
and palmitate treatment is associated with major changes
in the level of several other components of the machinery
of exocytosis that are not reproduced by miR34a overex-
pression (Fig. 7). Part of these changes may be linked to
chronic induction of a transcriptional repressor, inducible
cAMP early repressor, that we previously demonstrated to
target Rab27A, Noc2, and Granuphilin (50). Thus, although
the rise of miR34a may contribute to perturbing the
exocytotic process by reducing VAMP2 expression, it is
unlikely that the alteration of the level of this miRNA is the
main cause of the secretory dysfunction in palmitate-
treated cells.
To our knowledge, this is the first study reporting
changes in -cell miRNA expression under physiopatho-
logical conditions. Chronic hyperglycemia, prolonged ex-
posure to cytokines, or oxidized LDLs are all known to
cause pancreatic -cell dysfunctions (46,51). These ad-
verse conditions may also be associated with distinct
modifications of the miRNA expression profile. A precise
definition of the impact of these different physiopatholog-
ical conditions on miRNA expression will help in elucidat-
ing the causes of -cell failure and favor the definition of
new directions for the development of better tools for
prevention and treatment of diabetes.
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